FDA Reversal on Chembio Antibody Test Sends Stock Down 63%

(Bloomberg) -- Chembio Diagnostics stock lost more than half its value on Wednesday after U.S. regulators revoked its right to sell a test for Covid-19 antibodies over accuracy concerns.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.